The usefulness of evaluative outcome measures in patients with multiple sclerosis

被引:50
|
作者
de Groot, V.
Beckerman, H.
Uitdehaag, B. M. J.
de Vet, H. C. W.
Lankhorst, G. J.
Polman, C. H.
Bouter, L. M.
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, EMGO Inst, NL-1007 MB Amsterdam, Netherlands
关键词
multiple sclerosis; evaluative outcome measures; responsiveness; minimally important change; smallest real change;
D O I
10.1093/brain/awl223
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To select the most useful evaluative outcome measures for early multiple sclerosis, we included 156 recently diagnosed patients in a 3-year follow-up study, and assessed them on 23 outcome measures in the domains of disease-specific outcomes, physical functioning, mental health, social functioning and general health. A global rating scale (GRS) and the Expanded Disability Status Scale (EDSS) were used as external criteria to determine the minimally important change (MIC) for each outcome measure. Subsequently, we determined whether the outcome measures could detect their MIC reliably. From these, per domain the outcome measure that was found to be most sensitive to changes (responsive) was identified. At group level, 11 outcomes of the domains of physical functioning, mental health, social functioning and general health could reliably detect the MIC. Of these 11, the most responsive measures per domain were the Medical Outcome Study 36 Short Form sub-scale physical functioning (SF36pf), the Disability and Impact Profile (DIP) sub-scale psychological, the Rehabilitation Activities Profile sub-scale occupation (RAPocc) and the SF36 sub-scale health, respectively. Overall, the most responsive measures were the SF36pf and the RAPocc. In individual patients, none of the measures could reliably detect the MIC. In sum, in the early stages of multiple sclerosis the most useful evaluative outcome measures for research are the SF36pf (physical functioning) and the RAPocc (social functioning).
引用
收藏
页码:2648 / 2659
页数:12
相关论文
共 50 条
  • [1] Outcome measures for multiple sclerosis
    Osborne, Lisa
    Noble, J.
    Maramba, Inocencio
    Jones, Kerina
    Middleton, Rodden
    Lyons, Ronan
    Ford, David
    Reed, Phil
    [J]. PHYSICAL THERAPY REVIEWS, 2014, 19 (01) : 24 - 38
  • [2] Outcome Measures in Multiple Sclerosis
    Bermel, Robert
    Waldman, Amy
    Mowry, Ellen M.
    [J]. MULTIPLE SCLEROSIS INTERNATIONAL, 2014, 2014
  • [3] Clinical outcome measures in multiple sclerosis
    Amato, Maria Pia
    Portaccio, Emilio
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 259 (1-2) : 118 - 122
  • [4] Outcome measures in multiple sclerosis studies
    Uitdehaag, B. M. J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 9 - 10
  • [5] Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis
    Molenaar, Pam C. G.
    Noteboom, Samantha
    van Nederpelt, David R.
    Krijnen, Eva A.
    Jelgerhuis, Julia R.
    Lam, Ka-Hoo
    Druijff-van de Woestijne, Gerrieke B.
    Meijer, Kim A.
    van Oirschot, Pim
    de Jong, Brigit A.
    Brouwer, Iman
    Jasperse, Bas
    de Groot, Vincent
    Uitdehaag, Bernard M. J.
    Schoonheim, Menno M.
    Strijbis, Eva M. M.
    Killestein, Joep
    [J]. JOURNAL OF NEUROLOGY, 2024, : 5958 - 5968
  • [6] The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis
    Dalton, C
    Barker, G
    MacManus, D
    Miszkiel, K
    Bates, D
    Blumhardt, L
    Hawkins, C
    Palace, J
    Sharief, M
    Swingler, R
    Young, C
    Miller, D
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (03): : 399 - 399
  • [7] Clinical outcome measures for research in multiple sclerosis
    Balcer, LJ
    [J]. JOURNAL OF NEURO-OPHTHALMOLOGY, 2001, 21 (04) : 296 - 301
  • [8] Outcome Measures in Clinical Trials for Multiple Sclerosis
    Caspar E. P. van Munster
    Bernard M. J. Uitdehaag
    [J]. CNS Drugs, 2017, 31 : 217 - 236
  • [9] Outcome Measures in Clinical Trials for Multiple Sclerosis
    van Munster, Caspar E. P.
    Uitdehaag, Bernard M. J.
    [J]. CNS DRUGS, 2017, 31 (03) : 217 - 236
  • [10] Clinical outcome measures in multiple sclerosis: A review
    Inojosa, Hernan
    Schriefer, Dirk
    Ziemssen, Tjalf
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (05)